Summary

India Host Cell Protein Testing Market Research Report Information by Product Type (PCR-based assays, ELISA-based assays, mass spectrometry-based assays and others), by End User (Contract Research Organizations, Biopharmaceutical Companies, and Others) Forecast to 2032

Major Players
India Host Cell Protein Testing Market is anticipated to register a healthy CAGR of 99.12% during the review period. Host cell proteins (HCPs) are process-related impurities created by the host organism during biotherapeutic manufacturing. During the purification process, many HCPs are removed from the finished product. They are proteins produced or encoded by the organisms that produce recombinant therapeutic proteins. Recombinant therapeutic proteins are typically produced by genetically modified prokaryotic or eukaryotic host cells through cell culture/fermentation technology.
High demand for biologics across the India and rising adoption of stringent regulatory guidelines for biopharmaceutical production in India are major factors driving the growth of the India host cell protein market. However, the issues related to the efficiency and accuracy of the test kits are expected to restrain the growth of the Indian market. Nevertheless, the growing government initiatives and increasing start-ups associated with the biopharmaceutical industry across India are attributed to creating lucrative opportunities for the Indian market.
Market Segmentation
Based on product type, the India host cell protein testing market has been segmented into PCR-based assays, ELISA-based assays, mass spectrometry-based assays and others. The ELISA-Based Assays segment held the largest market share in 2022, and Mass Spectrometry-Based Assays is the fastest-growing segment during the forecast period i.e., 2023 -2032.
Based on End User, the India host cell protein testing market has been segmented into contract research organizations, biopharmaceutical companies, and others.
Major Players
The key players operating in India host cell protein testing market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Abcam Limited, Enzo Life Sciences, Inc., Cytiva, Cygnus Technologies, LLC, Rockland Immunochemicals, Inc, Biogenes GmbH, and Krishgen BioSystems.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 16
3 RESEARCH METHODOLOGY 17
3.1 OVERVIEW 17
3.2 DATA FLOW 19
3.2.1 DATA MINING PROCESS 19
3.3 PURCHASED DATABASE: 20
3.4 SECONDARY SOURCES: 21
3.4.1 SECONDARY RESEARCH DATA FLOW: 22
3.5 PRIMARY RESEARCH: 23
3.5.1 PRIMARY RESEARCH DATA FLOW: 24
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 25
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 25
3.6.1 REVENUE ANALYSIS APPROACH 25
3.7 DATA FORECASTING 26
3.7.1 DATA FORECASTING TECHNIQUE 26
3.8 DATA MODELING 27
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 27
3.8.2 DATA MODELING: 28
3.9 TEAMS AND ANALYST CONTRIBUTION 29
4 MARKET DYNAMICS 31
4.1 INTRODUCTION 31
4.2 DRIVERS 31
4.2.1 HIGH DEMAND FOR BIOLOGICS ACROSS THE INDIA 31
4.2.2 RISING ADOPTION OF STRINGENT REGULATORY GUIDELINES FOR BIOPHARMACEUTICAL PRODUCTION 32
4.3 RESTRAINTS 33
4.3.1 ISSUES RELATED TO THE EFFICIENCY AND ACCURACY OF THE TEST KITS 33

4.4 OPPORTUNITY 34
4.4.1 GROWING GOVERNMENT INITIATIVES AND INCREASING START-UPS ASSOCIATED WITH BIOPHARMACEUTICAL INDUSTRY
ACROSS THE INDIA 34
5 MARKET FACTOR ANALYSIS 35
5.1 PORTER'S FIVE FORCES MODEL 35
5.1.1 THREAT OF NEW ENTRANTS 35
5.1.2 BARGAINING POWER OF SUPPLIERS 36
5.1.3 THREAT OF SUBSTITUTES 36
5.1.4 BARGAINING POWER OF BUYERS 36
5.1.5 INTENSITY OF RIVALRY 37
5.2 IMPACT OF COVID-19 ON THE INDIA HOST CELL PROTEIN MARKET 37
6 INDIA HOST CELL PROTEIN MARKET, BY TYPE 39
6.1 OVERVIEW 39
7 INDIA HOST CELL PROTEIN MARKET, BY END USER 42
7.1 OVERVIEW 42
8 COMPETITIVE LANDSCAPE 46
8.1 INTRODUCTION 46
8.2 MARKET SHARE ANALYSIS, 2022 46
8.3 COMPETITOR DASHBOARD 47
8.4 PUBLIC PLAYERS STOCK SUMMARY 48
8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 48
9 COMPANY PROFILES 49
9.1 ENZO LIFE SCIENCES, INC 49
9.1.1 COMPANY OVERVIEW 49
9.1.2 FINANCIAL OVERVIEW 50
9.1.3 PRODUCTS OFFERED 50
9.1.4 KEY DEVELOPMENTS 50
9.1.5 SWOT ANALYSIS 50
9.1.6 KEY STRATEGIES 51
9.2 BIO-RAD LABORATORIES, INC 52
9.2.1 COMPANY OVERVIEW 52
9.2.2 FINANCIAL OVERVIEW 53
9.2.3 PRODUCTS OFFERED 54
9.2.4 KEY DEVELOPMENTS 54
9.2.5 SWOT ANALYSIS 55
9.2.6 KEY STRATEGIES 55
9.3 ABCAM LIMITED 56
9.3.1 COMPANY OVERVIEW 56
9.3.2 FINANCIAL OVERVIEW 57
9.3.3 PRODUCTS OFFERED 57
9.3.4 KEY DEVELOPMENTS 58
9.3.5 KEY STRATEGIES 58
9.4 THERMO FISHER SCIENTIFIC INC 59
9.4.1 COMPANY OVERVIEW 59
9.4.2 FINANCIAL OVERVIEW 60
9.4.3 PRODUCTS OFFERED 61
9.4.4 KEY DEVELOPMENTS 61
9.4.5 SWOT ANALYSIS 61
9.4.6 KEY STRATEGY 61
9.5 CYTIVA 62
9.5.1 COMPANY OVERVIEW 62
9.5.2 FINANCIAL OVERVIEW 62
9.5.3 PRODUCTS OFFERED 63
9.5.4 KEY DEVELOPMENTS 63
9.5.5 SWOT ANALYSIS 63
9.5.6 KEY STRATEGIES 63
9.6 CYGNUS TECHNOLOGIES, LLC 64
9.6.1 COMPANY OVERVIEW 64
9.6.2 FINANCIAL OVERVIEW 65
9.6.3 PRODUCTS OFFERED 65
9.6.4 KEY DEVELOPMENTS 68
9.6.5 KEY STRATEGY 68
9.7 AGILENT TECHNOLOGIES, INC 69
9.7.1 COMPANY OVERVIEW 69
9.7.2 FINANCIAL OVERVIEW 70
9.7.3 PRODUCTS OFFERED 70
9.7.4 KEY DEVELOPMENTS 71
9.7.5 SWOT ANALYSIS 71
9.7.6 KEY STRATEGIES 71

9.8 ROCKLAND IMMUNOCHEMICALS, INC 72
9.8.1 COMPANY OVERVIEW 72
9.8.2 FINANCIAL OVERVIEW 72
9.8.3 PRODUCTS/SERVICES OFFERED 73
9.8.4 KEY DEVELOPMENTS 73
9.8.5 KEY STRATEGIES 73
9.9 BIOGENES GMBH 74
9.9.1 BIOGENES GMBH 74
9.9.2 FINANCIAL OVERVIEW 74
9.9.3 PRODUCTS OFFERED 75
9.9.4 KEY DEVELOPMENTS 75
9.9.5 KEY STRATEGIES 75
9.10 KRISHGEN BIOSYSTEMS 76
9.10.1 COMPANY OVERVIEW 76
9.10.2 FINANCIAL OVERVIEW 76
9.10.3 PRODUCTS OFFERED 77
9.10.4 KEY DEVELOPMENTS 77
9.10.5 KEY STRATEGIES 77
10 DATA CITATIONS 78